Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

47 results about "Body cells" patented technology

Definition of body cell. 1: somatic cell-opposed to germ cell. 2: the one of two cells produced by division of the generative cell in the pollen grain of certain gymnosperms that in turn divides to produce two male nuclei or cells.

Method for cultivating triploid kelp sporophyte and identifying ploidy of induced protonema

The invention discloses a method for cultivating triploid kelp sporophytes and identifying ploidy of induced protonema, and belongs to the field of kelp breeding. The method is based on a capillary glass needle separation technology for inducing filamentous somatic cells by kelp and a molecular biological technology for specific marking of sex of kelp gametophytes. The sex specific marker of the kelp gametophyte is used for carrying out PCR (Polymerase Chain Reaction) amplification and 1.5% agarose gel electrophoresis detection on the separated induction protonema single-cell cloning line, so that the genetic sex of the kelp induction protonema can be accurately identified; and the ploidy of the induced protonema of a part of varieties (lines) is directly determined from the molecular level. The method for synchronously detecting the genetic sex and ploidy of the induced protonema breaks through the bottlenecks of chromosome counting and flow cytometry operation, can be completed only through one-time PCR amplification, and is simple, convenient, rapid, short in time consumption, capable of completing detection of a plurality of samples at the same time and low in cost.
Owner:SHANDONG ORIENTAL OCEAN SCI TECH

Single-chain donanemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of donanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain natalizumab antibody-transferrin fusion protein for enhanced efficacy and indications

PendingUS20260049147A1Hybrid immunoglobulinsTransferrinsNatalizumab AntibodyExocytosis
The efficacy and indication of natalizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single chain adalimumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of adalimumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors
Owner:RNA THERAPEUTICS INC

Single-chain ranibizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ranibizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain alemtuzumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ALEMTUZUMAB do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain MEDI1341 antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of MEDI1341 do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain dupilumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of dupilumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain solanezumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain prasinezumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of prasinezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain semorinemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of semorinemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain cetuximab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of cetuximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain tildrakizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of tildrakizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Method and device for inducing pluripotent stem cells

PendingCN121495830ACulture processArtificial cell constructsStem cell productReprogramming
The invention discloses a method and device for inducing pluripotent stem cells, and relates to the technical field of cell culture.The inducing method specifically comprises the following steps that S1, target cells are separated and treated and inoculated into a three-dimensional support containing a culture medium, and meanwhile a space gradient microenvironment is established; s2, performing periodic physical stimulation on each target body cell by adopting low-intensity pulse ultrasound, and activating a signal channel corresponding to mechanical transduction in cooperation with a small molecule inducer; s3, adding a photosensitive metabolism intermediate precursor or a photoresponsive regulating agent into the three-dimensional bracket, and performing time-limited irradiation; by simulating a signal environment of embryonic development, directional migration and gradual reprogramming of each target body cell are effectively guided, accurate intervention on different target body cells is realized, meanwhile, a reprogramming effect is verified from multiple angles, and the quality and stability of a pluripotent stem cell product are guaranteed.
Owner:LANGZISEL BIOTECHNOLOGY (XIANYANG) CO LTD

Single-chain gantenerumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of gantenerumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

A gene-regulation-based tumor stem cell inhibiting drug and preparation method thereof

The application discloses a tumor stem cell inhibiting medicine based on gene regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The medicine takes a targeted interference fragment of a tumor stem cell specific regulation gene TSC-G as a core active component, and is composed of only the targeted interference fragment and a modified liposome. The modified liposome is composed of DSPC, Chol and PEG-DSPE in a specific ratio, and has high targeting property and good stability. The preparation method comprises four steps of targeted interference fragment synthesis, modified liposome preparation, medicine assembly and purification, and has simple process and high purity. The medicine can effectively inhibit self-renewal, proliferation and differentiation of tumor stem cells, the tumor stem cell inhibition rate is greater than or equal to 88%, the tumor volume inhibition rate in vivo is greater than or equal to 78%, the medicine has no toxicity to normal body cells, the technical scheme is unique, the medicine can be used for clinical tumor treatment, and the problem of tumor recurrence and drug resistance can be solved from the root.
Owner:CLAYYURE GENE TECH CO LTD

Single-chain eculizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of eculizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Covered endoprosthesis with improved branch access

An endoprosthesis may include an expandable framework including an anchoring portion and a body portion extending axially from the anchoring portion, the body portion having a plurality of body cells; and a polymeric cover disposed on at least a portion of the expandable framework. The anchoring portion includes a first transverse flange and a second transverse flange proximate the first transverse flange, the first and second transverse flanges being configured to secure the anchoring portion at an orifice of a body lumen. The body portion includes a window through a side of the body portion, the window occupying space equivalent to at least two of the plurality of body cells. The window is devoid of the polymeric cover and any other structure within a perimeter of the window.
Owner:BOSTON SCIENTIFIC SCIMED INC

Single-chain belimumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of belimumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors
Owner:RNA THERAPEUTICS INC

Single-chain infliximab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of infliximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain ustekinumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ustekinumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain trastuzumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of trastuzumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain lecanemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of lecanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain canakinumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of canakinumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain cinpanemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of cinpanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain basiliximab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of basiliximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain ofatumumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ofatumumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain aducanumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of Aducanumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors
Owner:RNA THERAPEUTICS INC

Single-chain romiplostim antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of romiplostim do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain ravulizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ravulizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC